
European Association of Urology Annual Congress (EAU23)
Milan 10 March 2023 - 13 March 2023

Immune-related AEs tied to improved survival in bladder cancer patients on atezolizumab
In patients with locally advanced or metastatic urothelial cancer patients receiving atezolizumab treatment, immune-related adverse events (AEs) were associated with improved survival outcomes, according to an analysis of individual participant data from the IMvigor210 and IMvigor211 studies.

MV-140 vaccine proven safe, effective in recurrent UTI
Immunotherapy with MV-140 (Uromune) successfully prevents urinary tract infections (UTIs) in patients suffering from recurrent UTIs, suggest the results of a prospective study presented at the 38th Annual EAU Congress (EAU 2023).

Investigational imaging agent holds promise for diagnosing renal cancer
In the pivotal phase III ZIRCON study, PET/CT imaging with 89Zr-DFO-girentuximab, an investigational imaging agent, demonstrated potential in the noninvasive identification of clear-cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses (IDRM).






